These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35902132)

  • 21. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
    Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
    Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of microbial and indoleamine-2,3-dioxygenase-derived tryptophan metabolites with immune activation in healthy adults.
    Riazati N; Kable ME; Newman JW; Adkins Y; Freytag T; Jiang X; Stephensen CB
    Front Immunol; 2022; 13():917966. PubMed ID: 36248784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The kynurenine pathway in brain tumor pathogenesis.
    Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
    Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDO Targeting in Sarcoma: Biological and Clinical Implications.
    Nafia I; Toulmonde M; Bortolotto D; Chaibi A; Bodet D; Rey C; Velasco V; Larmonier CB; Cerf L; Adam J; Le Loarer F; Savina A; Bessede A; Italiano A
    Front Immunol; 2020; 11():274. PubMed ID: 32194552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Fong W; Li Q; Ji F; Liang W; Lau HCH; Kang X; Liu W; To KK; Zuo Z; Li X; Zhang X; Sung JJ; Yu J
    Gut; 2023 Nov; 72(12):2272-2285. PubMed ID: 37770127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
    Ghonime MG; Saini U; Kelly MC; Roth JC; Wang PY; Chen CY; Miller K; Hernandez-Aguirre I; Kim Y; Mo X; Stanek JR; Cripe T; Mardis E; Cassady KA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of IDO and AHR blockers reduces the migration and clonogenicity of breast cancer cells.
    Soltani-Asl M; Azimnasab-Sorkhabi P; Yoshinaga TT; de Oliveira Massoco C; Kfoury JR
    Immunol Res; 2024 Jun; 72(3):430-437. PubMed ID: 38153625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic cellular viroimmunotherapy for canine high-grade gliomas.
    Cloquell A; Mateo I; Gambera S; Pumarola M; Alemany R; García-Castro J; Perisé-Barrios AJ
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
    Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J
    Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cell-expressed IDO alleviates atherosclerosis by expanding CD4
    Wang F; Liu M; Ma D; Cai Z; Liu L; Wang J; Zhang W; Zhao L; Zhai C; Xu Y
    Int Immunopharmacol; 2023 Mar; 116():109758. PubMed ID: 36706593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
    J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
    Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
    Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
    Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
    Front Immunol; 2022; 13():832263. PubMed ID: 35371054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
    Guastella AR; Michelhaugh SK; Klinger NV; Fadel HA; Kiousis S; Ali-Fehmi R; Kupsky WJ; Juhász C; Mittal S
    J Neurooncol; 2018 Sep; 139(2):239-249. PubMed ID: 29667084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
    Heidari F; Ramezani A; Erfani N; Razmkhah M
    Int Rev Immunol; 2022; 41(3):346-363. PubMed ID: 33118843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 40. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.